Targeting ErbB3 Receptor in Cancer with Inhibitory Antibodies from Llama

The human ErbB3 receptor confers resistance to the pharmacological inhibition of EGFR and HER2 receptor tyrosine kinases in cancer, which makes it an important therapeutic target. Several anti-ErbB3 monoclonal antibodies that are currently being developed are all classical immunoglobulins. We took a...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Igor E. Eliseev, Valeria M. Ukrainskaya, Anna N. Yudenko, Anna D. Mikushina, Stanislav V. Shmakov, Anastasiya I. Afremova, Viktoria M. Ekimova, Anna A. Vronskaia, Nickolay A. Knyazev, Olga V. Shamova
Format:	Artigo
Język:	Inglês
Wydane:	MDPI AG 2021-08-01
Seria:	Biomedicines
Hasła przedmiotowe:	cancer therapy monoclonal antibodies receptor tyrosine kinases HER3 antibody purification conformational stability
Dostęp online:	https://www.mdpi.com/2227-9059/9/9/1106
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!